Free Trial

Abbott Laboratories (ABT) Stock Forecast & Price Target

Abbott Laboratories logo
$114.23 +1.81 (+1.61%)
(As of 12/20/2024 05:31 PM ET)

Abbott Laboratories - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Sell
0
Hold
4
Buy
11

Based on 15 Wall Street analysts who have issued ratings for Abbott Laboratories in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 15 analysts, 4 have given a hold rating, and 11 have given a buy rating for ABT.

Consensus Price Target

$130.71
14.43% Upside
According to the 15 analysts' twelve-month price targets for Abbott Laboratories, the average price target is $130.71. The highest price target for ABT is $149.00, while the lowest price target for ABT is $117.00. The average price target represents a forecasted upside of 14.43% from the current price of $114.23.
Get the Latest News and Ratings for ABT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Abbott Laboratories and its competitors.

Sign Up

ABT Analyst Ratings Over Time

TypeCurrent Forecast
12/22/23 to 12/21/24
1 Month Ago
11/22/23 to 11/21/24
3 Months Ago
9/23/23 to 9/22/24
1 Year Ago
12/22/22 to 12/22/23
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
11 Buy rating(s)
12 Buy rating(s)
9 Buy rating(s)
9 Buy rating(s)
Hold
4 Hold rating(s)
4 Hold rating(s)
2 Hold rating(s)
4 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$130.71$130.07$123.33$117.80
Forecasted Upside14.43% Upside10.63% Upside8.47% Upside8.04% Upside
Consensus Rating
Moderate Buy
Moderate Buy
Moderate Buy
Moderate Buy

ABT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ABT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Abbott Laboratories Stock vs. The Competition

TypeAbbott LaboratoriesMedical CompaniesS&P 500
Consensus Rating Score
2.73
2.81
2.51
Consensus RatingModerate BuyModerate BuyModerate Buy
Predicted Upside14.43% Upside25,828.93% Upside14.52% Upside
News Sentiment Rating
Positive News

See Recent ABT News
Positive News
Positive News
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
11/5/2024Barclays
3 of 5 stars
 Boost TargetOverweight ➝ Overweight$143.00 ➝ $149.00+26.65%
10/17/2024Sanford C. Bernstein
3 of 5 stars
 Boost TargetOutperform ➝ Outperform$133.00 ➝ $138.00+17.37%
10/17/2024UBS Group
4 of 5 stars
 Boost TargetBuy ➝ Buy$143.00 ➝ $146.00+24.14%
10/17/2024Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetHold ➝ Hold$120.00 ➝ $125.00+5.91%
10/17/2024Mizuho
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetNeutral ➝ Neutral$115.00 ➝ $130.00+10.34%
10/17/2024Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight ➝ Equal Weight$107.00 ➝ $117.00-0.70%
10/17/2024Piper Sandler
Subscribe to MarketBeat All Access for the recommendation accuracy rating
A. Maeder
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost TargetOverweight ➝ Overweight$131.00 ➝ $133.00+12.88%
10/14/2024Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingOutperform ➝ Buy$122.00 ➝ $129.00+10.28%
10/8/2024Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$125.00 ➝ $130.00+13.33%
10/8/2024Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOutperform$130.00+14.69%
10/1/2024Evercore ISI
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOutperform ➝ Outperform$120.00 ➝ $124.00+8.87%
9/19/2024Piper Sandler Companies
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageOverweight$131.00+14.04%
8/22/2024Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy ➝ Buy$119.00 ➝ $127.00+13.95%
7/30/2024Edward Jones
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 DowngradeBuy ➝ Hold
5/30/2024The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$121.00+20.11%
12/13/2023Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight ➝ Overweight$116.00 ➝ $121.00+13.70%
7/21/2023Wolfe Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 UpgradeUnderperform ➝ Peer Perform
4/20/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetOverweight$118.00 ➝ $122.00+9.56%
4/17/2023BTIG Research
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$125.00 ➝ $130.00+25.05%
3/31/2023Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetMarket Perform$90.00 ➝ $102.00+2.95%
3/30/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$125.00 ➝ $115.00+16.61%
1/26/2023Stifel Nicolaus
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetBuy$110.00 ➝ $125.00+12.35%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Saturday at 08:10 AM ET.


Should I Buy Abbott Laboratories Stock? ABT Pros and Cons Explained

These pros and cons were generated based on recent news and financial data from MarketBeat in order to provide readers with the fastest and most accurate insights. They were last updated on Thursday, December 12, 2024. Please send any questions or comments about these Abbott Laboratories pros and cons to contact@marketbeat.com.

Abbott Laboratories
Bull Case

green Wall Street bull icon

Here are some ways that investors could benefit from investing in Abbott Laboratories:

  • Abbott Laboratories recently reported earnings of $1.21 per share, exceeding analysts' expectations, which indicates strong financial performance and effective management.
  • The company has a solid market capitalization of approximately $200 billion, reflecting its stability and growth potential in the healthcare sector.
  • Abbott Laboratories has a current stock price of $113.86, which is below the consensus price target of $130.07, suggesting potential for price appreciation.
  • With a dividend yield of 1.93% and a consistent payout ratio of 66.87%, investors can expect regular income from dividends, making it an attractive option for income-focused investors.
  • The stock has received a "Moderate Buy" consensus rating from analysts, with twelve analysts issuing buy ratings, indicating strong confidence in the company's future performance.

Abbott Laboratories
Bear Case

red Wall Street bear icon

Investors should be bearish about investing in Abbott Laboratories for these reasons:

  • The stock has a relatively high price-to-earnings (P/E) ratio of 34.51, which may suggest that it is overvalued compared to its earnings, potentially limiting future price growth.
  • Abbott Laboratories has a beta of 0.73, indicating lower volatility compared to the market, which may not appeal to investors seeking high-risk, high-reward opportunities.
  • Despite recent revenue growth of 4.9% year-over-year, the healthcare sector can be subject to regulatory changes and market fluctuations that may impact future earnings.
  • The company has a debt-to-equity ratio of 0.32, which is relatively low, but any increase in debt could affect its financial stability and investor confidence.
  • Recent analyst ratings have varied, with some firms issuing hold ratings, which may indicate uncertainty about the stock's short-term performance.

ABT Forecast - Frequently Asked Questions

According to the research reports of 15 Wall Street equities research analysts, the average twelve-month stock price forecast for Abbott Laboratories is $130.71, with a high forecast of $149.00 and a low forecast of $117.00.

15 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Abbott Laboratories in the last twelve months. There are currently 4 hold ratings and 11 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" ABT shares.

According to analysts, Abbott Laboratories's stock has a predicted upside of 14.43% based on their 12-month stock forecasts.

Abbott Laboratories has been rated by research analysts at Barclays, Evercore ISI, Jefferies Financial Group, Mizuho, Morgan Stanley, Oppenheimer, Piper Sandler, Raymond James, Royal Bank of Canada, Sanford C. Bernstein, and UBS Group in the past 90 days.

Analysts like Abbott Laboratories less than other "medical" companies. The consensus rating score for Abbott Laboratories is 2.73 while the average consensus rating score for "medical" companies is 2.81. Learn more on how ABT compares to other companies.


This page (NYSE:ABT) was last updated on 12/21/2024 by MarketBeat.com Staff
From Our Partners